by Dr. Joseph Mercola STORY AT-A-GLANCE One paper compared Merck’s data on molnupiravir against peer-reviewed data on ivermectin and found ivermectin has a low side effect profile, costs less than molnupiravir and is more effective against SARS-CoV-2 Clinical Trials data show Merck gathered 1,850 participants but released data on only 762 in the non-hospitalized arm […]